AGC Biologics, Faron to manufacture cancer immunotherapy

By The Science Advisory Board staff writers

May 5, 2020 -- Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.

Under the deal, AGC will manufacture the biopharmaceutical firm's Clevegen cancer immunotherapy treatment. A humanized anti-Clever-1 antibody, Clevegen targets Clever-1-positive tumor-associated macrophages and converts these highly immunosuppressive M2 macrophages into immune-stimulating M1 macrophages. The macrophage-directed immuno-oncology switch may be used alone or in combination with other cancer treatments, according to the companies.

AGC and Faron noted that data from Faron's ongoing phase II MATINS trial have shown that Clevegen is safe and well-tolerated. In addition, there have been early clinical benefits in patients who have exhausted all other treatment options, the firms said.

AGC Biologics, AdaptVac partner on COVID-19 vaccine
AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.
Genomic landscape of osteosarcomas reveals why immunotherapy may not be effective
Immune profiling of osteosarcoma has revealed why immune checkpoint inhibitors might not be an effective treatment option for patients with this rare...
T cells work as a team to fight infection
Immune cells may be better at sensing each other than previously thought, according to a new study published in Immunity on February 11. Researchers...
Improving melanoma immunotherapies by regulating Treg proliferation
A new pathway to regulating anti-tumor immunity and increasing the effectiveness of PD-1 therapies was identified by scientists at Sanford Burnham Prebys...
Success of immunotherapies increased in cancer patients through co-treatment with monoclonal antibodies
A new approach provides evidence that it is possible to break down the protective wall surrounding tumor cells, therefore making immunotherapies more...

Copyright © 2020

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter